Sanofi US
Cambridge
Massachusetts
United States
201 articles about Sanofi US
-
Following a partial hold on another lead candidate last year, Sanofi is reinvigorating its MS pipeline with a Phase II win for its investigational anti-CD40L antibody frexalimab.
-
The U.S. Supreme Court unanimously ruled Amgen’s cholesterol drug Repatha patents invalid, ending a protracted legal battle with competitors Sanofi and Regeneron.
-
As insulin prices skyrocket, pharmas and PBMs faced pointed critique from the Senate HELP Committee, led by Sen. Bernie Sanders (I-VT).
-
The French pharma drops another BTK inhibitor program from Principia and an anti-TNFa from Ablynx.
-
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
4/25/2023
ALX Oncology Holdings Inc. today announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a next generation CD47 blocker, and SARCLISA.
-
Sanofi and Regeneron’s Dupixent (dupilumab) met its primary and all secondary endpoints in the Phase III BOREAS trial, significantly reducing severe exacerbations in COPD.
-
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
3/13/2023
Provention Bio, Inc. today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions.
-
Sen. Bernie Sanders (I-VT), chairman of the Senate’s Health, Education, Labor and Pensions Committee, sent a letter to Sanofi and Novo Nordisk urging them to lower insulin prices.
-
The FDA approved Sanofi and Sweden-based Sobi’s efanesoctocog alfa, now marketed as Altuviiio, to treat bleeding in adults and children with hemophilia A.
-
Glooko Announces Global Collaboration with Sanofi for SoloStar® Pen Connectivity with New Device SoloSmart®
2/23/2023
Glooko Inc. ("Glooko"), today announced that they have entered into a partnering agreement with Sanofi to increase their support of people living with diabetes and healthcare professionals, by integrating SoloSmart with the Glooko® platform.
-
The FDA accepted the BLA for and granted Pfizer's maternal RSV vaccine candidate priority review.
-
Sanofi’s global head of R&D, John Reed, is leaving his position to pursue another opportunity outside the company, the French multinational announced Monday.
-
Sanofi is discontinuing its Phase III study of tolebrutinib, an investigational BTK inhibitor for myasthenia gravis.
-
Sanofi licensed CytoReason's inflammatory bowel disease model in a multi-million dollar bid to identify new therapies for IBD and Crohn’s and colitis.
-
Sanofi Selects THREAD as Global Decentralized Clinical Trials Provider
1/17/2023
THREAD , the leading technology and consulting service provider enabling electronic clinical outcome assessments (eCOA) and decentralized clinical trials (DCTs), announced today its five-year collaboration with innovative global health care company, Sanofi.
-
Amgen’s Repatha may cause cardiac harm, according to a reassessment of the biologic’s late-stage trial data.
-
Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.
-
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
12/16/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults and adolescents with eosinophilic esophagitis (EoE).
-
The FDA greenlit Libtayo plus chemotherapy to treat patients with advanced NSCLC irrespective of EGFR, ALK or ROS1 aberrations. It is the drug’s second approval in this space.
-
Sanofi entered into a partnership with Insilico Medicine to develop drugs for up to six targets. The deal is worth a potential $1.2 billion.